Inhibikase Therapeutics Inc Financials
This page shows Inhibikase Therapeutics Inc (IKT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Investor funding, not customer revenue, is the core operating engine, building a cash-heavy balance sheet despite rising losses.
From FY2023 to FY2025, financing inflows totaled about$220.3M , turning a$9.2M cash balance into a much larger reserve. By FY2025, cash reached$178.8M while liabilities stayed modest at$8.3M , showing the company scaled funding mainly through equity rather than debt.
The most important operating metric here is cash runway: FY2025 operating cash use of
Spending is expanding on both fronts, with R&D at
Financial Health Signals
Inhibikase Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Inhibikase Therapeutics Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Inhibikase Therapeutics Inc reported a net loss of $48.3M while operations used $27.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Inhibikase Therapeutics Inc reported an operating loss of $52.0M against $3.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Inhibikase Therapeutics Inc's EBITDA was -$51.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 81.8% from the prior year.
Inhibikase Therapeutics Inc reported -$48.3M in net income in fiscal year 2025. This represents a decrease of 75.4% from the prior year.
Inhibikase Therapeutics Inc earned -$0.49 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Inhibikase Therapeutics Inc recorded an outflow of $27.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 45.2% from the prior year.
Inhibikase Therapeutics Inc held $178.8M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Inhibikase Therapeutics Inc's ROE was -27.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 1.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Inhibikase Therapeutics Inc invested $29.8M in research and development in fiscal year 2025. This represents an increase of 73.1% from the prior year.
Inhibikase Therapeutics Inc invested $13K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
IKT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $0-100.0% | $261K+111.0% | $123K-96.0% | $3.1M+343.9% | $698K |
| R&D Expenses | N/A | $29.8M+73.1% | $17.2M+26.4% | $13.6M+13.2% | $12.0M+6.0% | $11.4M+1170.9% | $894K |
| SG&A Expenses | N/A | $23.6M+107.0% | $11.4M+69.0% | $6.7M+8.3% | $6.2M-4.5% | $6.5M+148.1% | $2.6M |
| Operating Income | N/A | -$52.0M-81.8% | -$28.6M-42.3% | -$20.1M-10.8% | -$18.1M-22.8% | -$14.8M-423.9% | -$2.8M |
| Interest Expense | N/A | $3.7M+247.5% | $1.1M+0.8% | $1.1M+1324.9% | $74K+273.7% | $20K-32.2% | $29K |
| Income Tax | N/A | $0 | $0 | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$48.3M-75.4% | -$27.5M-44.6% | -$19.0M-5.4% | -$18.1M-22.1% | -$14.8M-419.2% | -$2.8M |
| EPS (Diluted) | — | -$0.49 | -$1.16 | -$3.16+26.2% | -$4.28 | -$0.81 | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IKT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $181.2M+83.8% | $98.6M+579.7% | $14.5M-41.8% | $24.9M-41.3% | $42.5M+187.3% | $14.8M |
| Current Assets | $180.1M+82.9% | $98.5M+592.8% | $14.2M-41.7% | $24.4M-42.6% | $42.5M+187.3% | $14.8M |
| Cash & Equivalents | $178.8M+83.4% | $97.5M+959.8% | $9.2M+28.0% | $7.2M-82.4% | $40.8M+192.0% | $14.0M |
| Total Liabilities | $8.3M+122.3% | $3.7M+5.8% | $3.5M-9.5% | $3.9M-3.8% | $4.1M-18.9% | $5.0M |
| Current Liabilities | $8.3M+122.3% | $3.7M+8.6% | $3.4M-7.0% | $3.7M-8.9% | $4.1M-14.1% | $4.7M |
| Long-Term Debt | N/A | N/A | $382K | N/A | $249K | N/A |
| Total Equity | $172.9M+82.3% | $94.9M+764.2% | $11.0M-47.8% | $21.0M-45.2% | $38.4M+292.6% | $9.8M |
| Retained Earnings | -$142.7M-51.1% | -$94.4M-41.1% | -$66.9M-39.7% | -$47.9M-60.5% | -$29.8M-298.4% | $15.0M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
IKT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$42.6M | -$27.8M-45.1% | -$19.1M-5.9% | -$18.1M-4.2% | -$17.4M-21.4% | -$14.3M-1165.9% | -$1.1M |
| Capital Expenditures | $0 | $13K | $0-100.0% | $14K-94.1% | $243K | $0 | N/A |
| Free Cash Flow | -$42.6M | -$27.8M-45.2% | -$19.1M-5.8% | -$18.1M-2.9% | -$17.6M-23.1% | -$14.3M | N/A |
| Investing Cash Flow | -$115.2M | $2.1M+105.5% | -$37.0M-417.5% | $11.7M+172.8% | -$16.0M | $0 | N/A |
| Financing Cash Flow | $111.3M | $108.5M+4.8% | $103.5M+1131.1% | $8.4M+4204.6% | -$205K-100.5% | $41.1M+172.8% | $15.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IKT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | -7712.0% | -14686.2% | -476.2% | -403.5% |
| Net Margin | N/A | N/A | -7304.7% | -14625.9% | -476.9% | -407.7% |
| Return on Equity | -27.9%+1.1pp | -29.0%+144.3pp | -173.3%-87.5pp | -85.8%-47.3pp | -38.5%-9.4pp | -29.1% |
| Return on Assets | -26.6%+1.3pp | -27.9%+103.3pp | -131.2%-58.8pp | -72.4%-37.6pp | -34.8%-15.6pp | -19.3% |
| Current Ratio | 21.70-4.7x | 26.37+22.2x | 4.13-2.5x | 6.59-3.9x | 10.47+7.3x | 3.13 |
| Debt-to-Equity | 0.050.0x | 0.040.0x | 0.03-0.2x | 0.19+0.2x | 0.01-0.5x | 0.51 |
| FCF Margin | N/A | N/A | -6947.9% | -14253.4% | -461.1% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Inhibikase Therapeutics Inc Ranks
Frequently Asked Questions
Is Inhibikase Therapeutics Inc profitable?
No, Inhibikase Therapeutics Inc (IKT) reported a net income of -$48.3M in fiscal year 2025.
What is Inhibikase Therapeutics Inc's EBITDA?
Inhibikase Therapeutics Inc (IKT) had EBITDA of -$51.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Inhibikase Therapeutics Inc's return on equity (ROE)?
Inhibikase Therapeutics Inc (IKT) has a return on equity of -27.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Inhibikase Therapeutics Inc's free cash flow?
Inhibikase Therapeutics Inc (IKT) recorded an outflow of $27.8M in free cash flow during fiscal year 2025. This represents a -45.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Inhibikase Therapeutics Inc's operating cash flow?
Inhibikase Therapeutics Inc (IKT) recorded an outflow of $27.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Inhibikase Therapeutics Inc's total assets?
Inhibikase Therapeutics Inc (IKT) had $181.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Inhibikase Therapeutics Inc's capital expenditures?
Inhibikase Therapeutics Inc (IKT) invested $13K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Inhibikase Therapeutics Inc spend on research and development?
Inhibikase Therapeutics Inc (IKT) invested $29.8M in research and development during fiscal year 2025.
What is Inhibikase Therapeutics Inc's current ratio?
Inhibikase Therapeutics Inc (IKT) had a current ratio of 21.70 as of fiscal year 2025, which is generally considered healthy.
What is Inhibikase Therapeutics Inc's debt-to-equity ratio?
Inhibikase Therapeutics Inc (IKT) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Inhibikase Therapeutics Inc's return on assets (ROA)?
Inhibikase Therapeutics Inc (IKT) had a return on assets of -26.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Inhibikase Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Inhibikase Therapeutics Inc (IKT) had $178.8M in cash against an annual operating cash burn of $27.8M. This gives an estimated cash runway of approximately 77 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Inhibikase Therapeutics Inc's Piotroski F-Score?
Inhibikase Therapeutics Inc (IKT) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Inhibikase Therapeutics Inc's earnings high quality?
Inhibikase Therapeutics Inc (IKT) reported a net loss of $48.3M while operations used $27.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Inhibikase Therapeutics Inc cover its interest payments?
Inhibikase Therapeutics Inc (IKT) reported an operating loss of $52.0M against $3.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.